ArticleNeural computing & applications2022
Learning vector quantization as an interpretable classifier for the detection of SARS-CoV-2 types based on their RNA sequences.
Article in Neural computing & applications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Utilizing genomic signatures to gain insights into the dynamics of SARS-CoV-2 through Machine and Deep Learning techniques.BMC bioinformatics · 2024Article
- Unsupervised identification of significant lineages of SARS-CoV-2 through scalable machine learning methods.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Towards Efficient and Accurate SARS-CoV-2 Genome Sequence Typing Based on Supervised Learning Approaches.Microorganisms · 2022Article
- A self-organizing world: special issue of the 13th edition of the workshop on self-organizing maps and learning vector quantization, clustering and data visualization, WSOM + 2019.Neural computing & applications · 2022Article
- The Resolved Mutual Information Function as a Structural Fingerprint of Biomolecular Sequences for Interpretable Machine Learning Classifiers.Entropy (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present an approach to discriminate SARS-CoV-2 virus types based on their RNA sequence descriptions avoiding a sequence alignment. For that purpose, sequences are preprocessed by feature extraction and the resulting feature vectors are analyzed by prototype-based classification to remain interpretable. In particular, we propose to use variants of learning vector quantization (LVQ) based on dissimilarity measures for RNA sequence data. The respective matrix LVQ provides additional knowledge about the classification decisions like discriminant feature correlations and, additionally, can be equipped with easy to realize reject options for uncertain data. Those options provide self-controlled evidence, i.e., the model refuses to make a classification decision if the model evidence for the presented data is not sufficient. This model is first trained using a GISAID dataset with given virus types detected according to the molecular differences in coronavirus populations by phylogenetic tree clustering. In a second step, we apply the trained model to another but unlabeled SARS-CoV-2 virus dataset. For these data, we can either assign a virus type to the sequences or reject atypical samples. Those rejected sequences allow to speculate about new virus types with respect to nucleotide base mutations in the viral sequences. Moreover, this rejection analysis improves model robustness. Last but not least, the presented approach has lower computational complexity compared to methods based on (multiple) sequence alignment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00521-021-06018-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.